For Q3 FY2026 ended March 31, 2026, ResMed reported revenue of $1.43 billion, up 10.8% year-over-year. Net income was $398.7 million, up 9.2%, and diluted EPS was $2.74, up 10.5%. Operating income grew 17.3% to $499.8 million. The company held $1.66 billion in cash and $404.2 million in long-term debt.
•Revenue increased 10.8% YoY to $1.43 billion.
•Net income rose 9.2% to $398.7 million.
•Diluted EPS grew 10.5% to $2.74.
•Operating income improved 17.3% to $499.8 million.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
ResMed develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and globally.
The company operates in two segments, Sleep and Breathing Health, and Residential Care Software. It offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home Including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring.
Its portfolio also includes NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry, and EasyCare Tx, a sleep lab solution AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings.
Its portfolio also includes myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance, and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system.
Additionally, it offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion.
Its portfolio also includes HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes, MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors, and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. Founded in 1989, ResMed is headquartered in San Diego, California.
ResMed Inc. develops, manufactures, and markets medical devices and cloud-based software for diagnosing, treating, and managing respiratory disorders, primarily sleep apnea. Its Sleep and Breathing Health segment offers sleep recorders like ApneaLink Air for diagnosis, portable devices such as NightOwl, and therapy management tools like myAir app and AirView cloud system. The Residential Care Software segment includes Brightree and HEALTHCAREfirst solutions for home medical equipment, pharmacy, orthotic/prosthetic, and home health/hospice organizations. ResMed serves customers in the United States and globally, focusing on improving patient outcomes through connected care.
Where is ResMed (RSMDF) listed and in which currency?
ResMed Inc. trades on the OTC Markets OTCPK exchange under the ticker symbol RSMDF. Its financials are reported in US Dollars (USD). While the company is headquartered in the United States, its primary listing is on the New York Stock Exchange (NYSE: RMD), but the OTC ticker RSMDF provides an alternative way for investors to trade the stock, particularly those outside the US or seeking over-the-counter access.
What sector and industry does ResMed (RSMDF) belong to?
ResMed Inc. operates in the Healthcare sector and is classified under the Medical Instruments & Supplies industry. This means the company designs and manufactures medical devices and supplies used by healthcare professionals and patients. Specifically, ResMed focuses on respiratory care, including sleep apnea diagnostic tools, ventilators, and cloud-connected software. Its products are essential for diagnosing and managing chronic respiratory conditions, making it a key player in the medical technology space.
Where is ResMed (RSMDF) headquartered and what markets does it serve?
ResMed Inc. is headquartered in the United States and serves customers globally. The company operates in two segments: Sleep and Breathing Health, and Residential Care Software. Its products are distributed in the US and internationally, with a strong presence in sleep clinics, hospitals, and home care settings. ResMed's cloud-based solutions like AirView and myAir enable remote patient monitoring, supporting healthcare providers worldwide. The company also offers software solutions through Brightree and HEALTHCAREfirst for home health and hospice organizations in the US.
What are some notable products and software solutions from ResMed (RSMDF)?
ResMed's product portfolio includes diagnostic devices like ApneaLink Air (for sleep apnea screening) and NightOwl (a portable, cloud-connected disposable device that measures AHI). For therapy management, it offers myAir, a personalized app for sleep apnea patients, and AirView, a cloud system for remote device monitoring. The company also provides connectivity modules for ventilation devices. In software, Brightree serves home medical equipment and pharmacy organizations, while HEALTHCAREfirst offers electronic health records, billing, and analytics for home health and hospice. These solutions aim to improve patient engagement and clinical outcomes.